Advanced search
Publication Cover
Emerging Microbes & Infections Volume 11, 2022 - Issue 1
Submit an article Journal homepage
2,493
Views
7
CrossRef citations to date
0
Altmetric
Coronaviruses

The SARS-CoV-2 inactivated vaccine enhances the broad neutralization against variants in individuals recovered from COVID-19 up to one year

Xinrong Zhoua Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People’s Hospital; The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, People’s Republic of ChinaView further author information
,
Lin Chenga Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People’s Hospital; The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0001-8066-527XView further author information
ORCID Icon,
Haiyan Wanga Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People’s Hospital; The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, People’s Republic of ChinaView further author information
,
Xuejiao Liaob Follow-up Department of Chronic Diseases, National Clinical Research Center for Infectious Disease, Shenzhen Third People’s Hospital; The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, People’s Republic of ChinaView further author information
,
Miao Wanga Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People’s Hospital; The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, People’s Republic of ChinaView further author information
,
Lanlan Weia Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People’s Hospital; The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, People’s Republic of ChinaView further author information
,
Shuo Songa Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People’s Hospital; The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, People’s Republic of ChinaView further author information
,
Bing Zhoua Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People’s Hospital; The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, People’s Republic of ChinaView further author information
,
Zhenghua Mab Follow-up Department of Chronic Diseases, National Clinical Research Center for Infectious Disease, Shenzhen Third People’s Hospital; The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, People’s Republic of ChinaView further author information
,
Huimin Guoa Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People’s Hospital; The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, People’s Republic of ChinaView further author information
,
Xiangyang Gea Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People’s Hospital; The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, People’s Republic of ChinaView further author information
,
Bin Jua Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People’s Hospital; The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, People’s Republic of China;c Guangdong Key Laboratory for Anti-Infection Drug Quality Evaluation, Shenzhen, People’s Republic of ChinaCorrespondence[email protected]
View further author information
&
Zheng Zhanga Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People’s Hospital; The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, People’s Republic of China;c Guangdong Key Laboratory for Anti-Infection Drug Quality Evaluation, Shenzhen, People’s Republic of China;d Shenzhen Research Center for Communicable Disease Diagnosis and Treatment of Chinese Academy of Medical Science, Shenzhen, People’s Republic of ChinaCorrespondence[email protected]
View further author information
 show all
Pages 753-756 | Received 22 Dec 2021, Accepted 14 Feb 2022, Published online: 03 Mar 2022

Figures & data

Figure 1. Neutralizing activities against WT SARS-CoV-2 and variants in convalescent individuals received the inactivated vaccine. (a) Plasma neutralizing activities against each SARS-CoV-2 strain in three follow-up time points were measured and shown in the values of 50% inhibition dilution (ID50). (b) The broad spectrum of plasma nAbs in three follow-up time points. The GMT of nAbs against each variant was compared to that against WT, respectively. The positive rates of nAbs were marked at the bottom of each column. (c) The durability of broadly nAbs post the boosted vaccination. Paired plasma samples were collected from five individuals at Week 2 (n = 4) or Week 4 (n = 1) and Month 3 post vaccination and then tested the neutralizing activities against WT SARS-CoV-2 and variants. “-” represents decreased neutralization activity, “+” represents increased neutralization activity. The paired t test is performed here. “****” means P < .0001, “***” means P < .001, “**” means P < .01, “*” means P < .05, “ns” means not significant. The GMT, fold-change, and significance of difference were labeled on the top. The limit of detection was 1:20 dilution. The data below the limit was set to 20 for visualization.

Figure 1. Neutralizing activities against WT SARS-CoV-2 and variants in convalescent individuals received the inactivated vaccine. (a) Plasma neutralizing activities against each SARS-CoV-2 strain in three follow-up time points were measured and shown in the values of 50% inhibition dilution (ID50). (b) The broad spectrum of plasma nAbs in three follow-up time points. The GMT of nAbs against each variant was compared to that against WT, respectively. The positive rates of nAbs were marked at the bottom of each column. (c) The durability of broadly nAbs post the boosted vaccination. Paired plasma samples were collected from five individuals at Week 2 (n = 4) or Week 4 (n = 1) and Month 3 post vaccination and then tested the neutralizing activities against WT SARS-CoV-2 and variants. “-” represents decreased neutralization activity, “+” represents increased neutralization activity. The paired t test is performed here. “****” means P < .0001, “***” means P < .001, “**” means P < .01, “*” means P < .05, “ns” means not significant. The GMT, fold-change, and significance of difference were labeled on the top. The limit of detection was 1:20 dilution. The data below the limit was set to 20 for visualization.
Supplemental material

Supplemental Material

Download Zip (3.6 MB)

Data availability statements

We are happy to share reagents and information in this study upon request.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.